Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00168922
Status:
UNKNOWN
Last Update Posted:
2006-04-27
First Post:
2005-09-09
Brief Title:
Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer SCLC
Sponsor:
Charite University Berlin Germany
Organization:
Charite University Berlin Germany
Study Overview
Official Title:
Phase II Study to Determine the Efficacy of Bendamustin Ribomustin in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy
Status:
UNKNOWN
Status Verified Date:
2001-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Determination of response rate Assessment of toxicity and determination of time to progression
Detailed Description:
Phase II Study to determine the efficacy of BendamustinRibomustin in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None